Our rich pipeline of drug programmes has been entirely generated in-house using the Benevolent Platform™, which can work across therapeutic areas.

  • Target ID
  • Chemistry and Lead Optimisation
  • Preclinical
  • Phase I
  • Phase II
BEN-8744 Ulcerative Colitis
BEN-28010 Glioblastoma Multiforme
BEN-34712 ALS
Parkinson's disease
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Chronic Kidney Disease



We are actively exploring licensing discussions, and development and commercialisation partnerships for specific assets in our pipeline.

Contact us

UC - 360 x 269.jpg


From target identification to clinical development

Through the combined capabilities of our AI drug discovery Platform, scientific expertise and wet lab facilities, we have rapidly built a substantial portfolio that mixes both potentially best-in-class and first-in-class drug candidates.

BEN-8744: ulcerative colitis